SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Authors
Patel, M.Ascierto, P. A.
Thistlethwaite, Fiona C
Adkins, D. R.
Villaflor, V. M.
Galizia, D.
Calabro, L.
Di Maio, M.
D'Ambrosio, C.
Bertolini, A.
Damato, A.
Deantonio, C.
Yang, Y.
Kurup, D.
Abbadessa, G.
Affiliation
Drug Development, Florida Cancer Specialists/Sarah Cannon Research Institute,Sarasota, FL, USA;Issue Date
2022
Metadata
Show full item recordCitation
Patel M, Ascierto PA, Thistlethwaite F, Adkins DR, Villaflor VM, Galizia D, et al. SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 2022 Sep;33(7):S864-S5. PubMed PMID: WOS:000866211600695.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.828Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.828Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.828